AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.26) by 3.85 percent. This is a 56.14 percent increase over losses of $(0.57) per share from the same period last year.
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.26) by 3.85 percent. This is a 56.14 percent increase over losses of $(0.57) per share from the same period last year.
Comments